drugset / Trial / NCT00687037

Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power

NCT00687037

Phase 3 Completed 30 enrolled Sanofi
NaSingle-groupOpen-labelSupportive care

Summary

To prove the safety, in normal conditions, of the odontological use formulation of the product Cepacol Canela Power.

Timeline

Start
2008-01
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetylpyridinium Small molecule

Indications

No indication recorded.